BR0307691A - Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal - Google Patents

Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal

Info

Publication number
BR0307691A
BR0307691A BR0307691-1A BR0307691A BR0307691A BR 0307691 A BR0307691 A BR 0307691A BR 0307691 A BR0307691 A BR 0307691A BR 0307691 A BR0307691 A BR 0307691A
Authority
BR
Brazil
Prior art keywords
cytokine
composition
inhibition
modulating
animal
Prior art date
Application number
BR0307691-1A
Other languages
English (en)
Inventor
Subramanian Iyer
William L Johnson
Lance Nguyen
Steven C Ross
Ruye Xing
Original Assignee
Arkion Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkion Life Sciences filed Critical Arkion Life Sciences
Publication of BR0307691A publication Critical patent/BR0307691A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMPOSIçãO, FATOR DE INIBIçãO DE CITOCINA PURIFICADO E SEU MéTODO DE PURIFICAçãO, MéTODO DE INIBIçãO DA EXPRESSãO DE CITOCINA E MéTODO PARA MODULAR O SISTEMA IMUNOLóGICO DE UM ANIMAL". Trata-se de uma composição que compreende um fator de inibição de citocina (CIF) substancialmente purificado que tem determinadas características, incluindo a capacidade de inibir a transcrição do RNA do fator alfa (TNF-<244>) de necrose de tumor de citocinas pró-inflamatórias, interleucin 1-beta (IL-1 <225), e interleucin-2 (IL-2). Também é apresentado um método para purificar substancialmente o fator de inibição de citocina e um método para modular o sistema imunológico de um animal mediante o uso de tal composição.
BR0307691-1A 2002-02-11 2003-02-11 Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal BR0307691A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35603802P 2002-02-11 2002-02-11
US10/364,593 US7083809B2 (en) 2002-02-11 2003-02-11 Purified cytokine inhibitory factor
PCT/US2003/004020 WO2003068152A2 (en) 2002-02-11 2003-02-11 Purified cytokine inhibitory factor

Publications (1)

Publication Number Publication Date
BR0307691A true BR0307691A (pt) 2005-01-11

Family

ID=27669260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307691-1A BR0307691A (pt) 2002-02-11 2003-02-11 Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal

Country Status (10)

Country Link
US (1) US7083809B2 (pt)
EP (1) EP1487465A4 (pt)
KR (1) KR20040105710A (pt)
CN (1) CN1279972C (pt)
AU (1) AU2003216227A1 (pt)
BR (1) BR0307691A (pt)
CA (1) CA2474360A1 (pt)
HK (1) HK1080749A1 (pt)
MX (1) MXPA04007694A (pt)
WO (1) WO2003068152A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471100B2 (en) 2006-09-29 2019-11-12 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods
US9028882B2 (en) 2005-05-02 2015-05-12 4Life Patents, Llc Nutraceutical gels
WO2007050607A2 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
EP2525819B1 (en) * 2010-01-19 2018-06-06 Robert Coifman Immunotherapy compositions and methods of treatment
WO2014166483A1 (de) * 2013-04-12 2014-10-16 Nawrocki Werner Ch Verfahren zur herstellung einer eiölzusammensetzung
US10632158B2 (en) 2016-06-23 2020-04-28 IgY Nutrition Use of a hyperimmune egg product to prevent and treat dysbiosis
US10450364B2 (en) 2017-02-13 2019-10-22 Arkion Life Sciences, Llc Hyperimmunized egg product for treatment of necrotic enteritis in poultry

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357272A (en) 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
CZ1497A3 (en) * 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
US5772999A (en) 1996-07-30 1998-06-30 Dcv Biologics, L.P. Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals
AU1173599A (en) * 1997-11-20 1999-06-15 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
AU2372400A (en) 1999-01-19 2000-08-07 Dcv, Inc. Egg anti-inflammatory composition and method of treating and preventing inflammation
EP1198475B1 (en) * 1999-07-23 2005-03-02 Arkion Life Sciences Highly purified cytokine activating factor and methods of use

Also Published As

Publication number Publication date
KR20040105710A (ko) 2004-12-16
US7083809B2 (en) 2006-08-01
EP1487465A4 (en) 2007-05-30
MXPA04007694A (es) 2004-11-10
CN1279972C (zh) 2006-10-18
WO2003068152A2 (en) 2003-08-21
CN1642562A (zh) 2005-07-20
HK1080749A1 (en) 2006-05-04
EP1487465A2 (en) 2004-12-22
AU2003216227A1 (en) 2003-09-04
US20030152641A1 (en) 2003-08-14
CA2474360A1 (en) 2003-08-21
WO2003068152A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
ATE435013T1 (de) Histon deazetylase enzym-hemmende hydroxamsäurederivate als neue entzündungshemmer zur hemmung der zytokinsynthese
SG148201A1 (en) Substituted imidazo ring systems and methods
SG149829A1 (en) Pyrazolopyridines and analogs thereof
BG108927A (en) INBIEBLES OF INTERLEVKIN - 1BETA - CONVERTING ENZYME, METHOD OF RECEIVING THEM, PHARMACEUTICAL COMPOSITION THAT CONTAINS AND USING THEM AS MEDICINAL
ES2178895T3 (es) Derivados de amida que son utiles como inhibidores de citoquinas.
RS20110578A2 (en) MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
DE60332358D1 (de) Protease-resistente modifizierte interferon alpha polypeptide
SG149828A1 (en) Alkoxy substituted imidazoquinolines
MX2008002414A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos.
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
CY1109328T1 (el) Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου
ATE555786T1 (de) 1-alkoxy 1h-imidazo-ringsysteme und verfahren
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
JO2473B1 (en) Pyrazoles as inhibitors of tumor necrosis factor
BR0208694A (pt) Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
BR0307691A (pt) Composição, fator de inibição de citocina purificado e seu método de purificação, método de inibição da expressão de citocina e método para modular o sistema imunológico de um animal
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
GEP20053590B (en) Phenyl Heterocyclyl Ether Derivatives as Serotonin Re-Uptake Inhibitors
AR024907A1 (es) Uso de inhibidores de la produccion y/o accion de la il-18 y composiciones farmaceuticas formuladas con dichos inhibidores para el tratamiento demetastasis de tumores.
GB2431107A (en) Hoki fish liver oil,fractions thereof and therapeutic uses

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.